The Swiss Office for Social Security announced today that Spinraza will be funded across all types of spinal muscular atrophy in Switzerland.
The office is authorised to issue such decisions for people upto the age of 20 who have a genetic confirmation of SMA, irrespective of how severe the symptoms are. This also includes those who have not yet developed SMA symptoms.
Another decision will be needed for older patients.
The office also specified carefully crafted stop criteria. Spinraza treatment may be discountinued in the following cases:
- For all SMA 1 patients: if there is functional deterioration on two subsequent assessment for which no explanation exists other than SMA progress.
- For newly diagnosed SMA 1 and presymptomatic patients: if there is no improvement of at least 4 CHOP-INTEND points or 1 HINE point (specified milestone positions) after 10 months of treatment at two subsequent assessments.
- For all type 2 and 3 patients: if there is functional deterioration on two subsequent assessment for which no other explanation exists other than SMA progress.
TreatSMA makes all efforts to make SMA treatments available to all those with SMA in the UK.
